Investigating the effects of omega-3 monoglycerides on inflammation in blood cells
Official title: Increased Inflammation-resolving Activity by Omega-3 Monoglycerides in Peripheral Blood Mononuclear Cells (PBMC).
Run by SCF Pharma · NCT05161702 · Data updated 2026-11-12
This study is testing if omega-3 monoglycerides can help reduce inflammation in blood cells for people dealing with inflammatory issues.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | SCF Pharma Industry-sponsored |
| Locations | 1 site (Rimouski, Quebec) |
| Status | Recruiting |
| Started | March 12, 2019 |
| Main results expected | December 31, 2026 |
| Study ends | January 1, 2027 |
| Registry record updated | April 17, 2026 |
| Trial ID | NCT05161702 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older who do not use omega-3 supplements or anti-inflammatory medications.
✕Probably not a fit
Patients currently using omega-3 supplements or anti-inflammatory medications may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the beneficial effects of omega-3 monoglycerides on the resolution of inflammation by utilizing peripheral blood mononuclear cells (PBMCs). Blood samples will be collected from participants to isolate PBMCs, which will then be treated with omega-3 monoglycerides and exposed to an inflammatory agent to assess changes in cell proliferation. The study seeks to understand how pre-metabolized omega-3 fatty acids can enhance the body's natural inflammation resolution processes. The findings could contribute to the development of new therapeutic products targeting inflammation.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively resolve inflammation and reduce related health issues.
How similar studies have gone: While this approach is innovative, previous studies have shown promise in using omega-3 fatty acids for inflammation resolution, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participant aged of at least 18 years old. Exclusion Criteria: * Participant who use omega-3 supplements and / or anti-inflammatory medication such as, but not limited to - Aspirin, Ibuprofen (Motrin, Advil), Celecoxib (Celebrex), diclofenac (Cambia, Cataflam, Voltaren ) within 7 days of day 1 of the study.
Where it's running
-
SCF Pharma
Rimouski, Quebec, Canada Recruiting
Study contacts
- Principal investigator: Samuel P Fortin, PhD — SCF Pharma
- Study coordinator: Samuel Fortin, PhD
- Email: sfortin@scfpharma.com
- Phone: 418-750-8590
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.